In-depth studies of the tumor–inflammation link have identified several blood markers as potential indicators of systemic inflammation and predictors of prognosis in patients with cancer, including the dNLR, C-reactive protein, albumin and LDH. This evidence concerns the gene ALB and neoplasm.